Testing NTQ5082 for IgA nephropathy
Treatments studied
Part of Immune system & allergy, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests an experimental drug called NTQ5082 for people with IgA nephropathy. It aims to see if the drug can reduce protein in the urine and protect kidney function.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and weigh at least 88 pounds.
- You have IgA nephropathy confirmed by a kidney biopsy within the last 8 years.
- You have protein in your urine (0.75 grams or more per day).
- Your kidneys are working at 30% or more (eGFR 30 or above).
- You have had two vaccines: meningococcal (ACYW135) and pneumococcal.
- You are taking a stable dose of blood pressure medicine (RAS inhibitor) for at least 12 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This phase 3 trial tests an experimental drug (HRS-5965) for people with IgA nephropathy (a kidney disease). It aims to find out if the drug can help reduce protein in the urine and protect kidney function. To join, you must have had a kidney biopsy showing IgA nephropathy within the past 8 years and have significant protein in your urine despite taking standard treatments.
This trial tests a new drug, SHR-2173, for people with IgA nephropathy who still have a lot of protein in their urine despite standard care. The goal is to see if it can help protect kidney function.
This early-phase study tests a new drug called YKST02 for people with primary IgA nephropathy, a kidney disease. It aims to see if the drug is safe and if it can help reduce kidney damage.
This phase 2a trial tests an experimental drug called RG002C0106 in people with primary IgA nephropathy. The goal is to see if the drug can reduce protein in the urine and protect kidney function.
This study tests an experimental drug called MY008211A for people with IgA nephropathy (a kidney disease). It aims to see if it can safely reduce protein in the urine and protect kidney function.
This trial tests an experimental medicine called NM8074 for people with IgA nephropathy, a type of kidney disease. It aims to see if NM8074 can help protect your kidneys and reduce damage.
Hear when a new Primary IgA Nephropathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.